BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriatic Arthritis, Obesity | 04/26 | 08/26 | | |
NCT02682511: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension |
|
|
| Recruiting | 2 | 34 | US, RoW | Oral Ifetroban, Ifetroban, Oral Placebo | Cumberland Pharmaceuticals | Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases | 12/25 | 12/25 | | |
